• HUTCHMED signed an exclusive development and license deal with a GSK unit for HMPL-A830, a KRAS-EGFR antibody-targeted therapy conjugate.
• Deal grants GSK worldwide rights excluding Mainland China, Hong Kong, Macau, Taiwan; HUTCHMED keeps rights in those markets.
• US$ 110 million upfront payment; milestones up to US$ 1.19 billion; total potential consideration up to US$ 1.3 billion.
• Tiered royalties on annual net sales payable to HUTCHMED under the agreement.
• HUTCHMED to run global Phase I starting H2 2026; GSK to lead later development, commercialization outside retained territories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12317496), on September 03, 2026, and is solely responsible for the information contained therein.